Join us at JPM Healthcare 2025
AI-Driven Spatial Biomarkers Solutions for Clinical Trials and Diagnostics
Enabling next-gen diagnostics for ADCs, multi-specifics, and IO
Explore how Nucleai’s AI-driven innovations are accelerating breakthroughs in precision medicine:
- Unlock Spatial Biology’s Potential: Turn complex data into actionable insights with AI-powered spatial intelligence.
- Derisk Clinical Trials: Leverage AI diagnostics to accelerate trial enrollment and ensure success for next-gen therapies.
- Drive Innovation in ADCs: Meet the growing demand for precision biomarkers in the $30B ADC market.
Schedule a meeting with us at JPM 2025!
About Nucleai:
Nucleai is a leading AI-powered spatial biomarker company revolutionizing healthcare with geospatial analytics. Its platform translates complex tissue interactions into actionable insights, advancing the development of bi-specifics, ADCs, and immunotherapies. Backed by investors like Section 32, Sanofi, and M Ventures, Nucleai operates from Israel and Chicago..
Book a Meeting with Us
Avi Veidman
CEO and Co-Founder
Jonathan Daniels
SVP Strategy & BD
Please complete the form below to schedule a meeting with our team at JPM 2025